We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • Drug Products
    • Books
    • Books Library
    • Events
    • Form 483s
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
  • Device Products
    • Books
    • Books Library
    • Events
    • Form 483s
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Immunomedics Hit With CRL Over Breast Cancer Drug

Immunomedics Hit With CRL Over Breast Cancer Drug

FDA_Logo_Black_2016.gif
January 25, 2019

The FDA issued Immunomedics a complete response letter for a BLA seeking accelerated approval for its antibody-based breast cancer treatment, sacituzumab govitecan, for patients who have tried at least two prior treatments.

The problems cited in the CRL relate exclusively to chemistry, manufacturing and controls rather than the clinical trial programs, said Immunomedics’ senior director of investor relations, Chau Cheng.

The issues related to approvability “were exclusively focused on CMC matters, and no new clinical or preclinical data need to be generated. In addition, there will be no impact on our clinical trial programs,” Cheng said.

“The CRL was clearly unexpected as we felt we had fully addressed all the open questions during our interactions with the agency,” he said. “We continue to believe that all the issues are fully addressable.”

View today's stories

Pharmaceuticals Regulatory Affairs

Upcoming Events

  • 10Jan

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

  • 12Feb

    Increase Compliance, Reduce Risk with Integrated Digital Solutions: Create a Connected System and Streamline...

  • 17Mar

    FDA Data Integrity: For Device and Pharma Firms, and Their Suppliers

  • 19Mar

    SOPs and Policies for the 21st Century: Why Less is More

  • 20Apr

    17th Annual Medical Device Quality Congress

Featured Products

  • Biological-risk-eval-and-mngmnt-for-md-130x160

    Biological Risk Evaluation and Management for Medical Devices

  • Gmp-inspection-preparation-checklist-130x160

    GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • 483sonline-logo-430x250

    483sOnline.com Your Personal Pre-inspection Toolkit

  • Globalmarketimage

    International Devices and Diagnostics Monitor

  • Cryolife_logo

    CryoLife’s Thoracoabdominal Stent Graft Receives CE Mark

  • Patentstablabel

    House Judiciary Committee Advances Patent Abuse Legislation

New!

17th Medical Device Quality Congress

Learn More Here
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578.

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing